.Pharmacolibrary.Drugs.ATC.M.M05BA06_1 .Pharmacolibrary.Drugs.ATC.M.M05BA06_1| name: | IbandronicAcid_1 |
| ATC code: | M05BA06_1 | route: | oral |
| n-compartments | 2 |
Ibandronic acid (ibandronate) is a bisphosphonate drug used primarily for the prevention and treatment of osteoporosis in postmenopausal women. It reduces bone resorption by inhibiting osteoclast-mediated bone loss. Ibandronic acid is approved for clinical use in several countries as both oral and intravenous formulations.
Pharmacokinetic parameters in healthy postmenopausal women after 50 mg oral dose.
Croom, KF, & Scott, LJ (2006). Intravenous ibandronate: in the treatment of osteoporosis. Drugs 66(12) 1593–1603. DOI:10.2165/00003495-200666120-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16956306
Chiu, WY, et al., & Reginster, JY (2020). Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 31(1) 193–201. DOI:10.1007/s00198-019-05127-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/31642977
Pillai, G, et al., & Steimer, JL (2006). Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females. International journal of clinical pharmacology and therapeutics 44(12) 655–667. DOI:10.5414/cpp44655 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17190376